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Compared with “healthy” vessels, the extracellular matrix of atheromatous plaques
includes increased content of type-EIIIA-domain– containing fibronectin. Apoli-
poprotein E-null mice engineered to produce fibronectin lacking this alternatively
spliced exon exhibit reduced atherosclerosis. Diminished hypercholesterolemia
and reduced macrophage foam cell formation may contribute to this phenotype.
Variations in the molecular composition ofthe extracellular matrix (ECM) play im-
portant roles during vascular remodeling in
pathophysiologic processes (ie, vasculogenesis
and angiogenesis, wound healing, and vascular
obstructive lesion formation).1 Fibronectin is a
ligand for fibrin, heparin, collagen, and several
integrins implicated in the recruitment of
blood leukocytes to the arterial endothelium.2
While several splice-variant forms of fibronec-
tin have been identified, the 2 major forms are
plasma fibronectin (pFN), which is produced
by hepatocytes, and cellular fibronectin (cFN),
which is produced locally by different cell
types and deposited and assembled into the
ECM.2 A single gene encodes for distinct fi-
bronectin moieties depending on alternative
RNA splicing of exons encoding for the
V/CS-1 segment (also known as the V exon),
extra type III repeat segments (known as
ED-A and ED-B in humans, or EIIIA and
EIIIB in rodents), and the (VC) region.
pFN lacks extra type III repeat segments,
whereas cFN contains variable amounts of
these alternative domains.
Although a causal link between fibronectin
and cardiovascular pathobiology has been dif-
ficult to establish because null mutations for
fibronectin cause embryonic lethality,3 evi-
dence exists implicating fibronectin in cardio-
vascular pathobiology2,4,5: (1) EIIIA-positive
fibronectin (EIIIA-FN) up-regulation is asso-
ciated with clinical and experimental hyper-
tension; (2) expression of EIIIA-FN, EIIIB-
FN, and fibronectin lacking both alternative
exons is rapidly induced after myocardial in-
farction in both humans and animal models;
(3) EIIIA-FN and EIIIB-FN forms, which are
not normally present in “healthy” vessels, are
induced in neointimal lesions; (4) elevated
plasma levels of circulating cFN have been
described in clinical syndromes with vascular
damage; and (5) in vivo studies using blocking
antibodies have implicated the alternative fi-
bronectin V/CS-1 segment in leukocyte re-
cruitment during murine atherosclerosis.
Recently, analysis of fibronectin condi-
tional knock-out mice revealed a role of pFN
in thrombus initiation, growth, and stability.6
Now, Tan and colleagues (page 11) directly
test the function of EIIIA-FN in atherosclero-
sis by engineering EIIIA-null (EIIIA/) mice
lacking the EIIIA exon. They crossed
EIIIA/mice with atherosclerosis-prone
apolipoprotein E–null (ApoE/) mice and
found as much as a 67% reduction in aortic
atherosclerosis in doubly deficient fat-fed
EIIIA/ApoE/mice compared with
ApoE/ controls. An intriguing observation
that deserves further examination is that
EIIIA/ApoE/ females display significant
protection at all time points assayed (8, 12, and
16 weeks of fat feeding), while males are pro-
tected only after 16 weeks. Compared with
ApoE/ controls, both male and female
EIIIA/ApoE/mice displayed dimin-
ished total plasma cholesterol levels, a reduc-
tion that is specific to the very low density li-
poprotein fraction. Increased EIIIA-FN
expression was found in both the plasma and
in endothelial cells and macrophages within
atherosclerotic lesions of ApoE/mice.
Moreover, in vitro foam cell formation by
ApoE/macrophages was associated with
increased EIIIA-FN mRNA expression, and
lipid accumulation in EIIIA/ApoE/
macrophages was reduced by 31% compared
with ApoE/ controls.
Collectively, the study by Tan and col-
leagues convincingly demonstrates an athero-
genic role of EIIIA-FN and suggests that this
form of fibronectin is functional in both
plasma lipoprotein metabolism and in macro-
phage foam cell formation. Future studies are
warranted to elucidate additional systemic
mechanisms and processes within the vessel
wall by which EIIIA-FN may contribute to
atherosclerosis. For example, the possibility
that EIIIA-FN may interact with specific li-
poprotein fractions and may affect leukocyte
recruitment should be investigated. More-
over, because endothelial and smooth muscle
cells cultured on different ECM components
display significant differences in proliferation,
migration, and apoptosis, comparing the phe-
notypic properties of vascular cells cultured on
EIIIA-FN, EIIIB-FN, and fibronectin lacking
EIIIA/ApoE/ mice are protected from atherosclerosis. See the complete figure in the article beginning
on page 11.
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both EIII segments may shed significant in-
sight into the role of distinct variants of fi-
bronectin in atherosclerosis. 
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ADAMTS-13, VWF, inflammation,
and thrombosis
----------------------------------------------------------------------------------------------------------------
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Inflammatory cytokines can stimulate the release of ultralarge VWF multimers
from endothelial cells, as well as affect ADAMTS-13 cleavage of VWF, thus dem-
onstrating another link between inflammation and thrombosis.
Systemic inflammation shifts the hemo-static balance in the direction of throm-
bosis. This has long been recognized by phy-
sicians who treat patients with cancer,
infections, autoimmune diseases, and preg-
nancy, as these systemic conditions (as well as
many others) are associated with a hypercoag-
ulable state. Thus the link between thrombosis
and inflammation continues to be the focus of
considerable attention, both in the laboratory
and in the clinic.
Interactions between platelets, leukocytes,
and the endothelium lie at the interface be-
tween thrombosis and inflammation, and these
interactions are pro-
foundly influenced by
the actions of inflamma-
tory cytokines. Ex-
amples of cytokines
with procoagulant in-
fluence include tumor
necrosis factor
(TNF-), interleukin-6
(IL-6), and IL-8,
which, among many
effects, are known to
stimulate expression of
tissue factor by mono-
cytes and macrophages
(TNF-),1 increase
platelet reactivity and
induce fibrinogen and
plasminogen activator
inhibitor-1 (PAI-1) ex-
pression by the liver (IL-
6),1,2 and activate endo-
thelial cells (TNF- and
IL-8).2,3
Building on this theme, Bernardo and col-
leagues in this issue of Blood (page 100) in-
crease our understanding of the mechanisms
by which TNF-, IL-6, and IL-8 exert their
procoagulant influence, which turns out to
involve the blood clotting protein von Wille-
brand factor (VWF) and ADAMTS-13, an
enzyme involved in the proteolytic processing
of VWF and deficient in the disease throm-
botic thrombocytopenic purpura (TTP).
VWF synthesized by endothelial cells ei-
ther is constitutively secreted into the circula-
tion in the form of low-molecular-weight mul-
timers or is stored in Weibel-Palade bodies,
and in response to endothelial cell agonists is
released in the form of ultralarge multimers
(ULVWF). ULVWF is the most adhesive
and reactive form of VWF and may lead to
spontaneous platelet aggregation if not fur-
ther processed by the ADAMTS-13 metal-
loprotease. Lack of ULVWF cleavage by
ADAMTS-13 is thought to be the primary
defect underlying TTP.
In this study, Bernardo and colleagues in-
vestigated whether ULVWF release from en-
dothelial cells and its subsequent cleavage by
ADAMTS-13 are affected by the inflamma-
tory cytokines TNF-, IL-6, and IL-8, as
these processes could represent potential links
between inflammation and thrombosis. First,
using an elegant system in which cultured en-
dothelial cells are subjected to defined flow
stress in vitro, the authors demonstrate that
TNF- and IL-8 (but not IL-6) stimulate the
release of ULVWF strings from human um-
bilical vein endothelial cells (HUVECs) in a
dose-dependent manner. As HUVECs lack an
IL-6 receptor, the absence of response with
IL-6 was not surprising; when the experiment
was repeated with IL-6 precomplexed with
soluble IL-6 receptor, ULVWF release was
seen (although not to the level of the other
cytokines).
The authors then turn their attention to
whether these cytokines can alter the ability of
ADAMTS-13 to cleave ULVWF. They show
that IL-6 (but not TNF- or IL-8) greatly
abrogates the ability of ADAMTS-13 to cleave
ULVWF strings under flowing, but not static,
assay conditions. As this interesting effect
is still observed when partially purified
ADAMTS-13 is pretreated with IL-6, the
authors speculate that IL-6 may physically
impair binding of ADAMTS-13 to ULVWF
under the shear stress of flowing conditions.
As the authors point out, this observation is
IL-8 and TNF-, but not IL-6, stimulated the release of ULVWF multimers. See
the complete figure in the article beginning on page 100.
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